BATM Advanced Communications Ltd (LSE:BVC) is taking good strides forward as evidenced by today’s investment in ADOR Diagnostics, according to house broker Shore Capital.
Ador is a molecular diagnostics company developing the disruptive NATlab molecular biology platform, notes the broker.
NATlab uses novel diagnostic technologies in its multiplex solution, with a focus on infectious diseases.
ADOR has had 11 patents issued in the US and eight internationally with others pending.
ShoreCap adds that strong underlying progress is being delivered across the development of BATM’s core span of technologies.
“These are visibly moving towards potential market inflexion points, thus presenting a profitable high-growth opportunity to investors.”
Asset allocation, with business strategy, is firmly focused on growth investment.
“We expect positive technology and revenue development news flow to continue," said the broker.
“With commercialisation, positive operating leverage to reported results should be expected in due course – leading to an increasingly attractive fundamental valuation.“